Literature DB >> 19577586

Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice.

Xi Chen1, Cheng Zhang, Hua Wang, Juan Xu, Zi-Hao Duan, Ying Zhang, Tao Yu, Wei Wei, De-Xiang Xu, Jian-Ming Xu.   

Abstract

Rifampicin is a well-known hepatotoxicant, but little is known about the mechanism of rifampicin-induced hepatotoxicity. The aim of this study was to characterize the expression and localization of hepatocyte tight junctions in rifampicin-induced cholestasis in mice. Cholestasis was induced by administration of rifampicin (200 mg/kg) for 7 consecutive days or treatment with a single dose of rifampicin (200 mg/kg) by gastric intubation. The expression of mRNA for hepatic zonula occludens (ZO)-1, ZO-2, ZO-3, occludin and claudin-1 was determined using RT-PCR. Localization of ZO-1 and occludin was detected using immunofluorescence. Results showed that there was an 82-fold increase in the conjugated bilirubin in serum in rifampicin-treated mice. In addition, an 8-fold increase in total bile acid in serum was observed after a seven-day administration of rifampicin. The integrity of hepatocyte ZO-1 and occludin was altered by a seven-day administration of rifampicin. Importantly, the integrity and intensity of hepatocyte tight junctions were altered as early as 30 min after a single dose of rifampicin. The expression of hepatic ZO-1 and ZO-2 mRNA was significantly decreased, beginning as early as 30 min and remaining a lower level 12 h after a single dose of rifampicin. Taken together, these results suggest that the altered integrity and internalization of hepatocyte tight junctions are associated with rifampicin-induced cholestasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19577586     DOI: 10.1016/j.taap.2009.06.022

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  9 in total

1.  Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.

Authors:  Ying-Ray Lee; N I Tien; Cheng-Li Lin; Hsin-Yi Shen; DA-Tian Bau; Yun-Ping Lim
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 2.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

3.  SEW2871 attenuates ANIT-induced hepatotoxicity by protecting liver barrier function via sphingosine 1-phosphate receptor-1-mediated AMPK signaling pathway.

Authors:  Zhenzhou Jiang; Luyong Zhang; Tingting Yang; Xue Wang; Yi Zhou; Qiongna Yu; Cai Heng; Hao Yang; Zihang Yuan; Yingying Miao; Yuanyuan Chai; Ziteng Wu; Lixin Sun; Xin Huang; Bing Liu
Journal:  Cell Biol Toxicol       Date:  2021-01-05       Impact factor: 6.691

4.  Protective Effects of Vitamin C and NAC on the Toxicity of Rifampin on Hepg2 Cells.

Authors:  Nasser Vahdati-Mashhadian; Mahmoud Reza Jafari; Nasim Sharghi; Toktam Sanati
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

5.  Rifampicin-Induced Hepatic Lipid Accumulation: Association with Up-Regulation of Peroxisome Proliferator-Activated Receptor γ in Mouse Liver.

Authors:  Jia-Hui Huang; Cheng Zhang; Da-Gang Zhang; Lu Li; Xi Chen; De-Xiang Xu
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

6.  Synthesis, in vitro and in vivo evaluation of 3β-[18F]fluorocholic acid for the detection of drug-induced cholestasis in mice.

Authors:  Stef De Lombaerde; Sara Neyt; Ken Kersemans; Jeroen Verhoeven; Lindsey Devisscher; Hans Van Vlierberghe; Christian Vanhove; Filip De Vos
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

7.  Fluorescent imaging for assessment of the effect of combined application of electroporation and rifampicin on HaCaT cells as a new therapeutic approach for psoriasis.

Authors:  Biliana Nikolova; Anelia Kostadinova; Borislav Dimitrov; Zhivko Zhelev; Rumiana Bakalova; Ichio Aoki; Tsuneo Saga; Iana Tsoneva
Journal:  Sensors (Basel)       Date:  2013-03-14       Impact factor: 3.576

8.  Danning tablets attenuates α-naphthylisothiocyanate-induced cholestasis by modulating the expression of transporters and metabolic enzymes.

Authors:  Lili Ding; Binfeng Zhang; Changsen Zhan; Li Yang; Zhengtao Wang
Journal:  BMC Complement Altern Med       Date:  2014-07-17       Impact factor: 3.659

9.  4-Phenylbutyrate protects against rifampin-induced liver injury via regulating MRP2 ubiquitination through inhibiting endoplasmic reticulum stress.

Authors:  Jing Chen; Hongbo Wu; Xudong Tang; Lei Chen
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.